Current Report Filing (8-k)
March 20 2018 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: March 19, 2018
(Date of earliest event reported)
ANAPTYSBIO,
INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-37985
|
|
20-3828755
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
10421 Pacific Center Court, Suite 200
San Diego, CA
|
|
92121
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(858)
362-6295
(Registrants Telephone Number, Including Area Code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02 Departure of Directors or Certain Officers; Election Of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b)
On March 19, 2018, James A. Schoeneck advised the Board of Directors (the
Board
) of AnaptysBio, Inc.
(
AnaptysBio
) that he would resign as a Class III independent director of AnaptysBio and as a member of the audit and compensation committees of the Board, effective immediately. Mr. Schoenecks resignation is
for personal reasons and is not the result of any disagreement with AnaptysBio on any matter relating to its operations, policies or practices. Following Mr. Schoenecks resignation, Dennis Fenton, Ph.D. was appointed to the audit
committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
AnaptysBio, Inc.
|
|
|
|
|
Date: March 20, 2018
|
|
|
|
By:
|
|
/s/ Dominic Piscitelli
|
|
|
|
|
|
|
Name: Dominic Piscitelli
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Aug 2024 to Sep 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Sep 2023 to Sep 2024